

EULAR 2025 Congress

June 11–14, 2025
Barcelona, Spain



TOP ABSTRACTS

To help navigate the exciting content being presented at the European Alliance of Associations for Rheumatology Congress (EULAR 2025), we have provided recommendations for the top abstracts to look out for in psoriasis and psoriatic arthritis.

EULAR 2025: Top abstracts in psoriasis and psoriatic arthritis

June 11–14, 2025

Oral abstracts			
#	Title	Date	Presenter
OP0089 View	Early intensive therapy with combination csDMARDs or TNF inhibitors are superior to standard step up care for the treatment of moderate to severe psoriatic arthritis: The 3-arm parallel group SPEED RCT	Wednesday, June 11	Laura Coates
OP0094 View	Biological sex-related differences in radiographic progression and relationship with early clinical response: Post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study in biologic-naïve participants with active psoriatic arthritis treated with guselkumab	Wednesday, June 11	Dafna D. Gladman
OP0096 View	Impact of sonelokimab, a novel IL-17A- and IL-17F-inhibiting Nanobody, on multidomain clinical outcomes in active psoriatic arthritis: Results from the randomized, double-blind, placebo-controlled Phase 2 ARGO trial	Wednesday, June 11	Iain McInnes
OP0106 View	Long term outcomes of methotrexate and leflunomide combination therapy compared to methotrexate monotherapy in psoriatic arthritis: A follow-up study of the COMPLETE PsA trial	Wednesday, June 11	Amy Peeters
OP0175 View	Establishing definitions for difficult-to-treat psoriatic arthritis (D2T-PSA) and complex-to-manage psoriatic arthritis (C2M-PSA): Insights from the group for research and assessment of psoriasis and psoriatic arthritis (GRAPPA) initiative	Thursday, June 12	Fabian Proft
LB0001 View	Efficacy and safety of deucravacitinib up to week 16 from POETYK PsA-1: A multicenter, randomized, double-blind, placebo-controlled, phase 3 study in patients with active psoriatic arthritis	Saturday, June 14	Désirée van der Heijde
LB0010 View	Inhibition of structural damage progression with guselkumab, a selective IL-23i, in participants with active PsA: Results through Week 24 of the phase 3b, randomized, double-blind, placebo-controlled APEX study	Saturday, June 14	Philip J. Mease

Posters	
#	Title
POS0496 View	Deucravacitinib in moderate to severe plaque psoriasis: 5-year, long-term safety and efficacy results from the phase 3 POETYK PSO-1, PSO-2, and LTE trials
POS0574 View	Sustained effectiveness of secukinumab in controlling disease activity in patients with psoriatic arthritis: 5-year results from SERENA
POS0816 View	VISIBLE: Guselkumab impact on psoriatic arthritis at Week 16 in participants with moderate to severe psoriasis across all skin tones
POS1038 View	High prevalence of inflammatory PsA-specific findings in patients with long-standing psoriasis but no musculoskeletal symptoms
POS1072 View	Icotrokinra, a targeted oral peptide that selectively blocks the interleukin-23-receptor, for the treatment of moderate-to-severe plaque psoriasis: Results through Week 24 of the phase 3, randomized, double-blind, placebo-controlled ICONIC-LEAD trial
POS1228 View	Cardiovascular and mortality outcomes in psoriatic arthritis patients treated with hydroxychloroquine: A 10-year retrospective analysis
POS1269 View	EULAR Points to consider for the definitions of difficult-to-manage and treatment-refractory psoriatic arthritis
POS1280 View	Real-world switching patterns for patients with psoriatic arthritis on first-line advanced therapies
POS1314 View	Icotrokinra, a novel targeted oral peptide, in patients with psoriatic disease: Exploratory assessments from a Phase 2 psoriasis study informing a Phase 3 clinical program in psoriatic arthritis
POS1329 View	Secukinumab demonstrates high long-term efficacy, drug survival, and osteoprotective effects in psoriatic arthritis and psoriasis: 48-month follow-up of the PSARTROS study



EULAR 2025

Follow us on X to keep up to date
with the latest from the congress

@psoriasis_hub



PsOPsAHub

Brought to you by

